Irritable Bowel Syndrome (IBS) is a gastrointestinal (GI) disorder causing constant abdominal pain, bloating of the abdominal region and extreme distress. IBS is comprised of a number of separate idiopathic disorders affecting different parts of the GI tract, and it has no identified organic cause. Though there is no cure for IBS, there are several drugs on the market that target the symptoms of IBS, but they only offer temporary relief to sufferers. In this article, I will explain what IBS is, how Synergy Pharmaceuticals (SGYP) is targeting the root cause of IBS, and how investors could potentially benefit from the results of its Phase IIb/III drug trial of SP-333.
IBS causes a lot of GI related discomfort. People with IBS experience diarrhea, constipation, bloating and a collection of other GI symptoms that cause extreme anguish and agony to patients. Several symptoms can lead to diagnosis of IBS, but when the matter is isolated and clinical tests are performed, the diagnosis shows no abnormalities. The accurate cause for developing IBS is yet unknown.
IBS is believed to cause psychiatric symptoms due to an imbalance in brain and GI tract communication. Due to the involvement of the brain, most patients are referred to psychotherapy, since victims of IBS are also known to suffer from anxiety and depression. Other treatments are prescribed to people for whom psychotherapy does not help. These treatments are known to provide just relief and do not completely cure IBS. To continue reading, click here.